Summary
We determined whether the intravenous administration of multilamellar vesicle liposomes (MLV) containing a lipopeptide analogue of a fragment from the cell wall of gram-negative bacteria (CGP 31 362) can render BALB/c mouse alveolar macrophages tumoricidal in situ and reduce the incidence of spontaneous lung metastasis of syngeneic renal carcinoma (RENCA) cells. Alveolar macrophages (a) incubated in vitro with MLV containing CGP 31 362 (MLV-31 362) and (b) harvested from mice injected i.v. with MLV-31 362 were rendered cytotoxic against the RENCA cells. Maximum cytotoxic activity of the macrophages was induced by injecting 5 µmol MLV consisting of 250 mg phospholipids and 0.5 mg CGP 31 362. The single i.v. injection of 5 µmol MLV-31 362 produced activation of macrophages that lasted for up to 4 days. Repeated i. v. injections of MLV-31 362 produced a continuous antitumor activity in alveolar macrophages. To study the lipopeptide's effects on metastasis, we injected the left kidneys of BALB/c mice with RENCA cells. The kidney with growing tumor was resected 10 days later and, after a further 2 days, groups of mice were injected i.v. with MLV-31 362 or with MLV-HBSS (twice weekly for 3 weeks). Treatment with MLV-31 362 significantly decreased the median number of spontaneous lung metastases. These data demonstrate that the systemic administration of MLV-31 362 can activate murine lung macrophages in situ and reduce the incidence of spontaneous RENCA lung metastases.
Similar content being viewed by others
References
Adams DO, Kao K-J, Farb R, Pizzo SV (1980) Effector mechanisms of cytolytically activated macrophages: II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neural proteases. J Immunol 124: 293
Brodt P, Blore J, Phillips NC, Munzer JS, Rioux JD (1989) Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide. Cancer Immunol Immunother 28: 54
Creaven PJ, Cowens JW, Brenner DE, Dadey BM, Han T, Huben R, Karakousis C, Frost H, LeSher D, Hanagan J, Andrejcio K, Cushman MK (1990) Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J Biol Response Mod 9: 492
Fidler IJ (1981) The in situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process. J Immunol 127: 1719
Fidler IJ (1985) Macrophages and metastasis — a biological approach to cancer therapy: presidential address. Cancer Res 45: 4714
Fidler IJ (1988) Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv Drug Delivery Rev 2: 69
Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G (1980) The design of liposomes to improve delivery of macrophageaugmenting agents to alveolar macrophages. Cancer Res 40: 4460
Fidler IJ, Sone S, Fogler WE, Barnes ZL (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78: 1680
Fidler IJ, Sone S, Fogler WE, Smith D, Braun DG, Tarcsay L, Gisler RJ, Schroit AJ (1982) Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. J Biol Response Mod 1: 43
Fidler IJ, Fogler WE, Tarcsay L, Schumann G, Braun DG, Schroit AJ (1983) Systemic activation of macrophages and treatment of cancer metastases by liposomes containing hydrophilic or lipophilic muramyl dipeptide. Immunopharmacol 2: 253
Fidler IJ, Fogler WE, Kleinerman ES, Saiki I (1985) Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human gamma interferon encapsulated in liposomes. J Immunol 135: 4289
Fidler IJ, Jessup JM, Fogler WE, Staerkel R, Mazumder A (1986) Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. Cancer Res 44: 994
Fidler IJ, Fan D, Ichinose Y (1989) Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma. Invasion Metastasis 9: 75
Fidler IJ, Nii A, Utsugi T, Brown D, Bakouche O, Kleinerman ES (1990) Differential release of TNF-α, IL 1, and PGE2 by human blood monocytes subsequent to interaction with different bacterial derived agents. Lymphokine Res 9: 449
Fogler WE, Fidler IJ (1986) The activation of tumoricidal properties in human blood monocytes by muramyl dipeptide requires specific intracellular interaction. J Immunol 136: 2311
Hibbs JB, Taintor RR, Vavrin Z (1987) Macrophage cytotoxicity: role forl-arginine deiminase and imino nitrogen oxidation to nitrate. Science 235: 473
Hudson MM, Snyder JS, Jaffe N, Kleinerman ES (1988) In vitro and in vivo effect of Adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators. Cancer Res 48: 5256
Ichinose Y, Bakouche O, Tsao JY, Fidler IJ (1988) Tumor necrosis factor and IL-1 associated with plasma membranes of activated human monocytes lyse monokine-sensitive but not monokine-resistant tumor cells whereas viable activated monocytes lyse both. J Immunol 141: 512
Key ME, Talmadge JE, Fogler WE, Bucana CD, Fidler IJ (1982) Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J Natl Cancer Inst 69: 1189
Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ (1989) Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 49: 4665
Lachman LB, Dinarello CA, Llansa ND, Fidler IJ (1986) Natural and recombinant human interleukin 1-β is cytotoxic for human melanoma cells. J Immunol 136: 3098
MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, Howard PE (1989) Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 81: 935
Mehta K, Lopez-Berestein G, Hersh EM, Juliano RL (1982) Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J Reticuloendothel Soc 32: 155
Murphy GP, Hrushesky WJ (1973) A murine renal cell carcinoma. J Natl Cancer Inst 50: 130
Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, Fidler IJ (1989) Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine [MTP-PE (CGP 19 835A)] in cancer patients. J Clin Oncol 7: 915
Nathan CF, Silverstein SC, Brukner LH, Cohn ZA (1979) Extracellular cytolysis by activated macrophages and granulocytes: II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med 149: 100
Nii A, Utsugi T, Fan D, Denkins Y, Pak C, Brown D, van Hoogevest P, Fidler IJ (1991) Development of liposomes containing a new lipopeptide CGP 31 362 for efficient activation of tumoricidal properties in monocytes and macrophages. J Immunother (in press)
Onozaki K, Matsushima K, Aggarwal BB, Saito T, Oppenheim JJ (1985) Human interleukin-1 is a cytocidal factor for several tumor cell lines. J Immunol 135: 3862
Phillips NC, Tsao M (1989) Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide. Cancer Res 49: 936
Phillips NC, Mora ML, Chedid L, Lefrancier P, Bernard JM (1985) Activation of tumoricidal activity of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res 45: 128
Raz A, Fogler WE, Fidler IJ (1979) The effect of experimental condition on the expression of in vitro mediated tumor cytotoxicity mediated by murine macrophages. Cancer Immunol Immunother 7: 157
Saiki I, Fidler IJ (1985) Synergistic activation by recombinant mouse interferon-γ and muramyl dipeptide of tumoricidal properties in mouse macrophages. J Immunol 135: 684
Salup RR, Herberman RB, Wiltrout RH (1985) Role of natural killer activity in the development of spontaneous metastasis in murine renal cancer. J Urol 134: 1236
Schroit AJ, Fidler IJ (1982) Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res 42: 161
Schroit AJ, Hart IR, Madsen J, Fidler IJ (1983) Selective delivery of drugs encapsulated in liposomes: natural targeting to macrophages involved in various disease states. J Biol Response Mod 2: 97
Sone S, Fidler IJ (1981) In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Cell Immunol 57: 42
Sone S, Tandon P, Utsugi T, Ogawara M, Shimizu E, Nii A, Ogura T (1986) Synergism of recombinant interferon gamma with liposomeencapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes. Int J Cancer 38: 495
Sone S, Utsugi T, Tandon P, Ogawara M (1986) A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state. Cancer Immunol Immunother 22: 191
Talmadge JE, Lenz BF, Klabansky R, Simon R, Rigs C, Guo S, Oldham RK, Fidler IJ (1986) Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyl tripeptide. Cancer Res 46: 1160
Urba WJ, Hatmann LC, Longo DL, Steis RG, Smith II JW, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC, Huber C, Herold M, Alvord WG, Snow S, Clark JW (1990) Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Cancer Res 50: 2979
Utsugi T, Nii A, Fan D, Pak CC, Denkins Y, van Hoogevest P, Fidler IJ (1991) Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages. Cancer Immunol Immunother 33: 285–292
van Hoogevest P, Fankhauser P (1989) An industrial liposomal dosage form for muramyl-tripeptide-phosphatidylethanolamine (MTP-PE). In: Lopez-Berestein G, Fidler IJ (eds). Liposomes in the therapy of infectious diseases and cancer. Liss, New York, p 453
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Utsugi, T., Dinney, C.P.N., Killion, J.J. et al. In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362. Cancer Immunol Immunother 33, 375–381 (1991). https://doi.org/10.1007/BF01741597
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01741597